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Introduction 14 
The discovery of norovirus in 1972
1
, changed the understanding of the aetiology of gastroenteritis, 15 
making it the virus to be identified as an agent of gastroenteritis in humans. 16 
Today, norovirus is recognised as one of the commonest human infections and estimated to be 17 
associated with 125 million cases and 35,000 deaths worldwide in 2010
2
. Better epidemiological 18 
surveillance and outbreak investigations
3
, coupled with wider implementation of molecular-based 19 
laboratory diagnostics
4
 are leading to better estimates of the burden of norovirus infections as well as 20 
improved outbreak control. 21 
Data from challenge studies of prototype norovirus vaccines
5, 6
 demonstrated that protection against 22 
infection and disease can be achieved, however there remain significant challenges to development 23 
of a norovirus vaccine. Recent advances in cell culture systems for norovirus
7, 8
 and current research 24 
investigating the distribution of norovirus-associated disease in the population, for whom the disease 25 
burden is greatest, understanding host susceptibility factors, how to deploy novel technologies 26 
detecting norovirus in food and environmental matrices, and methodologies for ascertaining cases, 27 
are important in increasing our understanding of norovirus. Answers to these will help design 28 
strategies for vaccine and antiviral development, and how these might be best deployed to control 29 
norovirus infection. 30 
 31 
Norovirus virology 32 
At the time of discovery, the virus was referred to as the Norwalk agent, but as other related viruses 33 
were described in association with gastroenteritis, they became known as Norwalk-like viruses 34 
(NLVs), or – based on their morphology by electron microscopy – small, round, structured viruses 35 
(SLSVs). Following the cloning and sequencing of the Norwalk agent genome in 1993
9
, and 36 
subsequently other NLVs
10
, defining the genetic relatedness of these viruses led to their 37 
reclassification in the Caliciviridae family of viruses under the genus Norovirus in 2002
11
. 38 
Classification of this genetically diverse group of viruses
12, 13
 has described six established
14
 39 
genogroups (GI-GVI), and a proposed seventh
15, 16
. Two genogroups (GI and GII) are important 40 
pathogens of humans (GII also contains pathogens of animals, but there is no evidence of zoonotic 41 
transmission
17
) and genogroups are further subdivided into genotypes: nine GI and twenty-two GII 42 
genotypes have been described
12-14
. Norovirus names are presented as genotypes, e.g. genogroup II-43 
genotype 4 (GII.4) and strains are named for the place and year of their first description: e.g. 44 
GII.4/New Orleans 2009
18
 or GII.4/Sydney 2012
19
. 45 
The norovirus genome is a single strand of positive-sense ribonucleic acid (+ssRNA) that is ~7700 46 
nucleotides in length, organised as three open reading frames (ORF1-3)
20
. The 5′-proximal ORF1 47 
encodes a polyprotein that is post-translationally processed by the virus-encoded protease into six 48 
non-structural proteins, including a genome-linked protein (VPg/NS5), protease (Pro/NS6) and an 49 
RNA-dependent RNA polymerase (RdRp/NS7). Both ORF2 and ORF3 encode a single protein each, 50 
VP1 and VP2 respectively, that are structural proteins involved in formation and stabilisation of the 51 
virus particle
21
. 52 
Norovirus particles are 27-35nm in diameter and comprised of 180 copies of the VP1 protein, which 53 
itself is organised into three main domains: N-terminal (N), shell (S) and protruding (P), which is 54 
further arranged as P1 (subdivided as P1.1 and P1.2) and P2
21
. In the mature infectious virus particle, 55 
the N domain is internal, and the P2 domain is the most external part of the virus, making it highly 56 
surface-exposed and placed to coordinate many of the interactions between norovirus and its host 57 
environment. 58 
The primary host cell receptor for human norovirus is unknown, but can interact with histo-blood 59 
group antigens (HBGAs)
22
; these are glycans expressed on epithelial cells and in mucosal secretions, 60 
which determine ABO blood type groups. Norovirus strains may use HBGAs as attachment factors or 61 
co-receptors
23
, and sites in the VP1 P2 domain have been identified as HBGA binding sites
24-29
. 62 
Synthesis of HBGAs occurs by sequential modification of a precursor, and the process is controlled 63 
by glycosyl-transferase enzymes from several genetic loci that exhibit polymorphism throughout the 64 
human population. The ABH and Lewis antigens are relevant to norovirus binding, and as such the 65 
phenotype of an individual for secretory ABH and Lewis antigens is a host susceptibility factor for 66 
norovirus infection. Specifically, individuals with a non-functional FUT2 gene, which encodes an α1,2-67 
fucosyltrasnferase, have a ‘non-secretor’ phenotype, and are more resistant to norovirus infection that 68 
‘secretor’ individuals
30, 31
. Polymorphism at this locus may modulate susceptibility to other causes of 69 
diarrhoeal disease
32
.  70 
Public health laboratory surveillance worldwide has demonstrated dominance of GII.4 viruses
33-36
, 71 
however other norovirus genotypes circulate consistently, if at a lower level, in the population. The 72 
GII.4 cluster of norovirus strains have been the most commonly detected noroviruses circulating 73 
worldwide since the mid-1990s, over time, distinct variants of the GII.4 virus evolve, emerge, and then 74 
recede to be replaced by a new variant
33
. Emergence of a new GII.4 variant is associated with higher 75 
levels of infection and illness in the population and increased numbers of outbreaks
37
, although 76 
severity of disease does not necessarily increase. These emergence events may be geographically 77 
contained (e.g. a 2003 variant emerged in Asia, and a 2006 variant spread in Europe)
38
, or may be 78 
global, with new variants emerging and spreading worldwide over the course of a single year (as seen 79 
in 2002
39
, 2006
40
, 2009
18
 and 2012
19
). 80 
Noroviruses have been shown to have high evolutionary rates, up to 10
-2
 substitutions/site/year in the 81 
VP1 protein
41
, due to the error-prone nature of the virus-encoded RdRp
42
. The rate of evolution is 82 
fastest in the P2 domain, which interacts with the host immune system. Immune response to 83 
norovirus infection appears to target this region of the virus capsid, and epitopes in this domain have 84 
been identified as important in defining the antigenic profile of GII.4 norovirus strains
43-47
, leading to 85 
the emergence of antigenically distinct viruses in the population, associated with epidemic/pandemic 86 
waves of gastroenteritis
33, 37, 48, 49
. 87 
The emergence of variant GII.4 strains is associated with mutations occurring in the virus at epitope A 88 
(VP1 amino acid positions 296-298, 368 & 372) and D (VP1 amino acid positions 393-395)
44, 50
. 89 
Mutations, particularly in epitopes A and D, will be selected for in the virus population if the mutations 90 
are such that existing immunity in the host population is evaded by the mutated virus, but the virus is 91 
otherwise not disadvantaged. Because much of the human population is exposed to antigenically 92 
similar noroviruses at a similar time, virus-specific immunity is likely similar between many people. As 93 
a result, the variant norovirus is advantaged, being more likely to successfully evade existing 94 
immunity, and subsequently establish more infections and be transmitted. In this way, the virus can 95 
spread quickly through the population. Eventually infections generate new immunological responses, 96 
which ultimately limit the success of this variant in the population, but in turn creates an ecological 97 
niche favourable for a new variant, and the process cycles again. This process has been observed for 98 
GII.4 noroviruses throughout the 1990s, 2000s and 2010s
19, 33, 37, 45, 47
. 99 
 100 
Norovirus surveillance 101 
Surveillance of norovirus is complicated because most people do not contact medical services when 102 
they are ill. In the UK, it is suggested that for each laboratory report of norovirus around 300 cases go 103 
unreported
51
. This is largely related to the nature of the illness itself. The virus is highly infectious with 104 
an estimated infectious dose of around 10-100 virus particles (virions) needed to cause infection
52
, 105 
with a high probability of infection from ingesting a single particle
53
. It has a short incubation period, 106 
anywhere between 12 and 72 hours, and symptoms typically last for around 24- 48 hours
54
. Despite 107 
these difficulties it is still recognised as the commonest cause of gastrointestinal disease, not just in 108 
the UK, but worldwide
55
. In the UK it is estimated between 3 and 4 million cases occur annually
51, 56
, 109 
at a cost of £106 million to patients and the health care services. In the USA this estimate is around 110 
21 million domestically acquired cases
57
. Infections with norovirus occur in all age groups, however, 111 
the highest incidence is in children aged less than five years
56, 58
. 112 
 113 
The illness is often described as generally mild and self-limiting. The description of a mild infection 114 
can trivialise the effect of the illness; in England it has been estimated that 3000 admissions occur 115 
annually as a result of norovirus infection in adults
59
 or 0.3% of emergency admissions in those aged 116 
over 65, and 0.1% in adults aged 16-64 years. The consequences of infection are also greater in 117 
vulnerable populations. In a study in the county of Avon, UK, hospital patients were ill for longer than 118 
care home residents and staff working in the hospitals or care home, with around 10% of inpatients 119 
affected still showing symptoms 7 days after becoming ill
60
. There is also evidence that norovirus can 120 
contribute to mortality in the elderly. Modelling of deaths suggests that norovirus is associated with 121 
20% in those aged over 65 years who died of infectious intestinal disease, and that 13% of deaths 122 
caused by non-infectious intestinal disease
61
. 123 
Public Health England have conducted surveillance of gastrointestinal disease outbreaks since 124 
1992
62
. Analysis of the first nine years of data highlighted the importance of norovirus outbreaks in 125 
hospitals; over 80% of all reported outbreaks in hospitals were suspected or confirmed as norovirus, 126 
and 25% of all general outbreaks occurred in hospitals
63
. 127 
 128 
Recent developments 129 
 130 
Surveillance 131 
Since the recognition of the importance of norovirus as a cause of GI disease a more detailed online 132 
surveillance system was set up in 2009
63
. The online system increased ascertainment of outbreaks in 133 
hospitals, with more outbreaks reported in the first year than the whole of the preceding system
63
. 134 
Both systems highlighted the increased activity during the winter months, and the considerable 135 
burden it places on NHS hospitals in England. The online system suggests around 13000 patients 136 
and 3000 staff are affected each year, moreover, almost 9000 bed days are lost because of 137 
restrictions to admissions during outbreaks
63
. 138 
The key to surveillance of norovirus is allying the epidemiology with surveillance of virology. It is often 139 
difficult to achieve this. Recording the number of outbreaks, and laboratory reports indicates levels of 140 
infection, but they cannot directly ally this knowledge of circulating strains of the virus. The activity 141 
recorded in both Public Health England’s hospital outbreak reporting scheme and laboratory reports 142 
suggests that seasonal activity varies considerably. The reasons for changes in seasonal activity 143 
need unpicking and modelling of changes in the circulating strains of norovirus against laboratory 144 
reporting provided evidence that modifications within the virus itself leads to changes in the 145 
epidemiology. In the autumn/winter of 2012 PHE recorded increased levels of norovirus activity; later 146 
attributed to the emergence of the Sydney 2012 strain
37
. However, other reasons have been 147 
proposed, such as changes in winter conditions such as falling temperature
64
. 148 
Given the difficulty in surveillance of norovirus infections from direct sources, other developments 149 
need to be explored. For example, social media could provide early indications of increasing activity. 150 
There are a number of publications looking at the use of internet search and social media postings to 151 
provide information on increased disease activity
65-67
. Other forms of syndromic surveillance have 152 
been used such as the use of telephone helpline data to map diarrhoea and vomiting
68
, difficulties 153 
with this approach fall mainly on disentangling the causes of the illness from syndromes (diarrhoea 154 
and vomiting). Norovirus is not the only cause of D&V and has a seasonality similar to that of 155 
rotavirus, similarly sapovirus has similar illness characteristics to norovirus. 156 
 157 
Virus culture systems 158 
Understanding the interactions of norovirus with host cells has been limited by the lack of an in vitro 159 
laboratory cell culture system. Attempts to establish conventional cell culture approaches were 160 
unsuccessful
69
, after which alternative approaches were developed
70, 71
, however, these were limited 161 
in their usefulness. 162 
More recently, progress has been made towards development of laboratory culture systems for 163 
human norovirus. Two systems have been described: one describes human norovirus replication in B 164 
cells
8
, and a second which describes human norovirus replication supported by stem cell-derived 165 
human enteroids
7
. These systems present exciting new opportunities to understand how norovirus 166 
interacts both with the host cell and with the host environment. 167 
The system using human enteroids
7
 provides a model for processes of norovirus replication such as 168 
attachment/entry, genome replication, and virus assembly/release can be interrogated in a biologically 169 
relevant cell type. Advances in these areas will be crucial for identifying targets for virus-specific 170 
interventions, and evaluating how effective different antiviral therapies can limit norovirus replication. 171 
Further insights into virus entry and egress will enhance understanding of the interactions between 172 
virus and host receptors and identify novel interactions between virus and host that serve as 173 
intervention targets, for example antibodies which interfere with attachment or release processes, 174 
thus neutralising free virus. 175 
The second system, in which norovirus replication is supported in B cells, uses commensal bacteria 176 
that express HBGAs to facilitate virus replication in this model
8, 72
. Analysis of norovirus replication in 177 
this system could enhance understanding of the interaction between norovirus and HBGAs – and 178 
identify how these interactions might be disrupted– but also what interactions might occur with, and 179 
what role might be played by, the microbiome during norovirus infection
73
. 180 
 181 
Norovirus vaccines 182 
Modelling studies have shown that norovirus vaccination would offer healthcare and economic 183 
benefit
74
. These could help control and prevent the large-scale and often protracted outbreaks often 184 
seen in healthcare settings
75
 and other settings such as in the military
76, 77
. 185 
Until very recently, development of candidate vaccines focussed on recombinant protein systems; 186 
expression of the norovirus capsid protein VP1 in vitro leads to self-assembly of the protein into virus-187 
like particles (VLPs) that are antigenically and morphologically identical to infectious virus, but lacking 188 
a genome, VLPs are entirely non-infectious
78
. 189 
Early clinical studies of responses in humans to immunisation with VLPs demonstrated they were 190 
immunogenic when delivered orally
79, 80
 or intranasally
81
. A randomised, double-blind placebo-191 
controlled trial conducted in healthy, susceptible adult volunteers investigated the safety and efficacy 192 
of vaccination using norovirus VLPs, followed by challenge with a homologous norovirus strain
6
. This 193 
trial demonstrated 70% of vaccine recipients had a virus-specific IgA response, and vaccination 194 
reduced the frequency of both infection and disease between placebo control group and vaccine 195 
recipients
6
. 196 
However, the prototype vaccine (and challenge strain) used in this trial was based on a single 197 
norovirus strain – the prototype GI.1 Norwalk virus/1968 – which is uncommon, detected in <1% of 198 
norovirus strains characterised per year in surveillance programmes in developed countries. As the 199 
most significant disease burden is associated with the GII.4 genocluster, any candidate vaccine would 200 
need to elicit immunity to GII.4 norovirus strains, and cross-react to antigenically distinct GII.4 201 
variants. A chimeric VLP was developed incorporating epitopes from antigenically distinct GII.4 202 
viruses
82
, and induced broadly-reactive antibody responses
83
. 203 
A subsequent trial incorporated the chimeric VLP into a GI.1/GII.4 bivalent vaccine formulation and 204 
demonstrated vaccine induced seroconversion in 90% of vaccine recipients, and reduced 205 
gastroenteritis following challenge
5
. However, the predefined primary endpoints were not achieved in 206 
this study, and further studies are necessary to assess how effective this candidate vaccine would be 207 
in the general population, and specifically in paediatric and elderly populations. Furthermore, studies 208 
must address both the duration of and the inter-/intra-genotype breadth of protection. 209 
 210 
Perspectives 211 
Clearly, significant progress has been made in understanding the virology and epidemiology of 212 
norovirus in humans: but there remain significant gaps in our knowledge, important for development 213 
of therapeutic and preventative interventions, and ascertaining norovirus disease burden to 214 
understand how these should be utilised, and to measure their effectiveness. This is true in all 215 
economic settings, but especially in low economic settings. 216 
One key question is to understand the emergence of norovirus strains. With no animal reservoir
17
, the 217 
virus must be sustained – and continuously evolve – in the human population. Using genomics 218 
approaches to measure and monitor virus diversity among circulating strains, and to characterise and 219 
measure whether observed genetic changes induce phenotypic changes will be crucial in developing 220 
the systems needed to understand and monitor emergence events, particularly those that lead to 221 
rapid pandemic spread of norovirus strains. There is increasing evidence that children may act as 222 
important reservoirs of norovirus, and the virus may exploit the more naïve immunological background 223 
in children to explore antigenic diversity, ultimately leading to virus diversification and subsequent 224 
emergence of novel strains
84
. 225 
Second, more detailed understanding of the burden of the disease, transmission dynamics and 226 
pathogenesis in risk groups, both those at risk of more severe disease (immunocompromised
85
, 227 
elderly
61
), and those more likely to come into contact with or are at higher risk of transmitting the virus 228 
(food-handlers
86
, healthcare workers
87
, military personnel
76
) is needed. There are complex 229 
epidemiological and virological questions relating to the distribution of norovirus-associated disease in 230 
the population, for whom the disease burden is greatest, as well as understanding host susceptibility 231 
factors. Integrated laboratory and epidemiological studies are crucial to investigate how norovirus is 232 
transmitted, disease attribution via different transmission pathways, how infections can be tracked in 233 
the population and during outbreaks, and what role susceptibility factors such as HBGA phenotype or 234 
the individual microbiome composition may play in norovirus infection, development of disease and 235 
outcomes. 236 
Third, alongside data on the direct burden of disease, enhanced data are needed to understand 237 
where interventions may alleviate transmission and disease overall, as many settings are interlinked. 238 
For example, administering a norovirus vaccine to patients in long term care homes might help 239 
prevent outbreaks in this environment, but might have limited effects on the population as a whole. 240 
However, it may be a worthwhile strategy if vaccination in care homes subsequently prevents 241 
outbreaks in hospitals and reduces bed blocking. 242 
With the recent advances in laboratory culture systems for norovirus
7, 88
, next generation sequencing 243 
technologies
89
, improved diagnostics
4
 and measuring phenotypic characteristics of noroviruses
90
, 244 
there are new opportunities to advance understanding of this common and important human 245 
pathogen. 246 
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